Fierce Pharma41m
J&J advances Stelara succession scheme with key FDA nod for Tremfya in Crohn's disease
With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...
Fierce Pharma57m
Alnylam's Amvuttra wins key approval in ATTR-CM, teeing up showdown with Pfizer
Despite growing competition in the transthyretin amyloid cardiomyopathy (ATTR-CM) field, Alnylam is hoping its RNA ...